Who Owns Nurix Therapeutics Stock?
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 114.88%
- Institutions (% of float)
- 116.13%
- Held by insiders
- 1.08%
- Institutional holders
- 298
- Institutions 98.9%
- Insiders 1.1%
- Public and other 0.0%
Who owns Nurix Therapeutics stock?
Institutional investors own about 114.9% of Nurix Therapeutics's shares, spread across 298 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 1.08% of NRIX.
The largest institutional holders are Blackrock Inc. (8.45%), Vestal Point Capital, LP (7.76%) and Deep Track Capital, Lp (7.45%). Together, the top 10 institutions control 59.1% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their NRIX positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of NRIX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 8.77M | 8.45% | -1.7% |
| Vestal Point Capital, LP | 8.05M | 7.76% | +23.9% |
| Deep Track Capital, Lp | 7.74M | 7.45% | +21.9% |
| Rubric Capital Management LP | 7.23M | 6.96% | +192.2% |
| FMR, LLC | 5.49M | 5.29% | -1.0% |
| Price (T.Rowe) Associates Inc | 5.44M | 5.24% | +65.2% |
| Morgan Stanley | 4.76M | 4.59% | -3.4% |
| State Street Corporation | 4.68M | 4.51% | -9.0% |
| Baker Bros. Advisors, LP | 4.66M | 4.49% | 0.0% |
| Vanguard Capital Management LLC | 4.50M | 4.33% | +1.6% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of NRIX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.27M | 3.15% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.60M | 2.50% |
| iShares Trust-iShares Russell 2000 ETF | 2.47M | 2.38% |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.78M | 1.71% |
| SmallCap World Fund Inc | 1.74M | 1.68% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.30M | 1.25% |
| T. Rowe Price Health Sciences Fund, Inc. | 1.19M | 1.14% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.11M | 1.07% |
| T. Rowe Price New Horizons Fund, Inc. | 1.10M | 1.06% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.05M | 1.01% |
Frequently asked questions
Who is the largest shareholder of Nurix Therapeutics?
Blackrock Inc. is the largest institutional shareholder of NRIX, owning 8.45% of shares outstanding (8.77M shares) as of its latest 13F filing.
What percentage of Nurix Therapeutics is owned by institutions?
Institutions own about 114.9% of NRIX shares and 116.1% of the public float.
How much of Nurix Therapeutics do insiders own?
Insiders, such as officers and directors, own about 1.08% of NRIX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.